Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

摘要: Abstract Objective: The purpose of this study was to define the response rate and toxicity topotecan in patients with ovarian cancer resistant first-line therapy. Methods: Twenty advanced or recurrent were enrolled a phase I/II protocol, an additional 16 treated following protocol closure at Washington University Medical Center. starting dose 1.25 mg/m 2 /day given intravenously over 30 min for 5 consecutive days. Patients eligible evaluation if they completed more than one cycle topotecan. All evaluated toxicity. Results: Of 28 evaluation, 26 both platinum paclitaxel prior treatment There four partial responders no complete total 14% (95% confidence interval: 4 33%). had exhibited primary resistance paclitaxel. Myelotoxicity major toxicity, 92% experiencing Gynecologic Oncology Group (GOG) grade 3 neutropenia 67% GOG thrombocytopenia. Other minimal easily managed. Fifty percent receiving tolerated equal greater dose. Conclusions: Topotecan exhibits activity Further is warranted less heavily pretreated combination other chemotherapeutic agents.